Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Previous Speakers

Diana Anderson

Diana Anderson

University of Bradford , UK

Yoshiaki Omura

Yoshiaki Omura

New York Medical College, USA

Michael Retsky

Michael Retsky

Harvard TH Chan School of Public Health , USA

Mohamed El-Far

Mohamed El-Far

Mansoura University, Egypt

Vanessa Bellat

Vanessa Bellat

Weill Cornell Medicine , USA

Shyam Mohapatra

Shyam Mohapatra

University of South Florida , USA

Melvin L DePamphilis

Melvin L DePamphilis

National Institute for Child Health & Human Development , USA

Wassil Nowicky

Wassil Nowicky

Ukrainian Anti-Cancer Institute , Austria

Cancer Genomics 2019

About Conference


We heartily welcome all the participants throughout the globe to participate in the conference titled 26th Cancer Genomics Congress: New Era for Cancer Prevention which is scheduled to commence on January 30-31, 2019, Abu Dhabi, UAE. This event would be a great opportunity to gather knowledge as well as experience in the field of Cancer Prevention and Control.

The Conference will provide a wonderful forum for you to refresh your knowledge base and explore the innovations in Chemotherapy, Gynecologic Cancer Prevention and Control, Clinical Oncology, Cancer Immunotherapy, Breast cancer etc.

The Conference will strive to offer plenty of networking opportunities, providing you with the opportunity to meet and interact with the leading scientists and researchers, speakers, to help enhance professional skills and meet the personal educational goal as well as friends and colleagues, different sponsors and exhibitors.

Cancer Genomics 2019 invites Speakers, Researchers, Exhibitors, and Sponsors from everywhere throughout the world to join the Cancer Genomics 2019 which will be held January 30-31, 2019, Abu Dhabi, UAE

Cancer Genomics 2019 is an International Conference which unites researchers, youthful analysts, students and making the Congress an ideal stage to share encounters, pick up and assess rising advancements in Cancer Prevention, Cancer Research, and Therapy over the globe.

Cancer Research widely goes from malignancy the study of sub-atomic level research to the execution of clinical preliminaries to assess and analyze uses of the different tumor medications and disease transmission. Numerous treatment choices for malignancy exist. The essential ones incorporate medical procedure, radiation treatment, chemotherapy, directed treatment, palliative care, hormonal treatment, and consolidated treatment modalities, and immunotherapy, for example, chemo-radiotherapy.

Motives to attend:

  • Keynote presentation along with interactions to galvanize the scientific community.
  • A wide track of exhibitors to showcase the new and emerging technologies.
  • Young Scientist/ Investigators Award geared towards best budding young research.
  • Links to political marketing resources in order to expand your business and research network.
  • Triumph of Awards, Certificates recognizes your commitment to your profession to encourage the nascent research.
  • Workshop and symposiums to reach the largest assemblage of participants from the Oncology community.

Why Should Attend??

  • The arranging group assembles eminent speakers covering the most recent advances in the field, fusing differing qualities in each sense. We likewise incorporate talks on most recent methodologies for concentrating these biological inquiries.
  • The conference focuses on the wider aspect of the scientific contribution to showcase the new scientific and technical advances in comparison to the ancient theories. Your perspective and our visualization together will set a platform for the exchange of ideas towards contribution to advanced innovation.
  • We encourage multidisciplinary approach as well. Not only speaker presentations but also workshops, exhibition, and networking opportunities are available. A Unique Opportunity for Advertisers and Sponsors at this International event.

Session/Tracks

Track 1: Cancer Genomics

Cancer is a group of diseases caused by changes in DNA that alter cell behaviour, causing uncontrollable growth and malignancy. Genomics is the study of the sequence of these letters in your DNA and how each string of letters passes information to help each cell in your body work properly. Cancer genomics aims to understand the genetic basis of tumour cell proliferation and the evolution of the cancer genome under mutation and selection by the body environment, the immune system and therapeutic interventions.

Track 2: Cancer Epigenomics and Metagenomics

Cancer epigenomic research is driven by the advancement of novel innovations and the usage of model living beings running from yeasts to plants to vertebrates. For quite a long time, the search for malignant growth qualities has concentrated on hereditary defects that were utilized as labels for identification of these qualities. With the acknowledgment that epigenetic adjustments, in particular DNA methylation events, are engaged with transcriptional changes in both tumor suppressor genes and oncogenes, methods have been created that help the identification of novel malignancy genes modified by DNA methylation alone or in mix with hereditary events. Metagenomics is another horizon in cancer research. Metagenomics has widened the extent of focusing on organisms in charge of inciting different kinds of diseases. About 16.1% of malignant growths are related with microbial disease. Metagenomics is an equitable method for recognizing and concentrate micro-organisms inside their environment.

Track 3: Cancer Immunogenomics

Cancer immunogenomics initially was encircled by research supporting the speculation that cancer mutations produced novel peptides seen as "non-self" by the immune system. The scan for these "neoantigens" has been encouraged by the mixture of new sequencing innovations, specific computational examinations, and HLA binding forecasts that assess physical changes in a cancer genome and decipher their capacity to create a resistant stimulatory peptide. The subsequent data can portray a tumor's neoantigen stack, its unit of penetrating resistant cell types, the T or B cell receptor collection, and direct the structure of a customized therapeutic.

Track 4: Hereditary Cancer Syndromes

Mutations for hereditary cancer syndromes are at high hazard for the advancement of tumors at an early age and in addition the synchronous or metachronous improvement of numerous tumors of the relating tumor spectrum. The hereditary reasons for some inherited disease disorders have just been distinguished. About 5% of all diseases are a part of an inherited malignant growth disorder. Clinical criteria are as of now accessible as per which numerous innate cancer syndromes can be analyzed or suspected and which indicate the way further molecular genetic analysis. A doctor can easily decide if these criteria are met by coordinated addressing about the patient's personal and family medicinal history. The recognizable proof of the causative germ line change in the family permits affirmation of the conclusion in the influenced individual and opens up the alternative of prescient testing in healthy relatives.

Track 5: Genomics of Adult and Pediatric Cancers

Identification of genomic modifications has given the perfect element to infer new procedures for molecular based precision medicine of adult and pediatric cancers including risk evaluation, non-invasive detection, molecular diagnosis and customized treatment. In addition, it is presently obvious that the spectra of genomic-based changes and systems in pediatric malignancies are not quite the same as those dominatingly happening in adult cancers. Adult Cancers on average show generously higher mutational weights compared with the childhood tumors. Collecting proof likewise recommends that the kind of genomic adjustments often experienced in adult cancer is not quite the same as those saw in pediatric malignancies.

Track 6: Systems Biology and Drivers of Cancer

Cancer systems biology perceives that numerous individual disciplines and data types can be helpfully conveyed to hold up under, alone or in combination, to methodically think about malignant growth. The assorted variety of communications among cancer system biologists, who originate from fields, for example, cancer biology, organic chemistry, bioinformatics, engineering, mathematics, material science, and software engineering, can prompt novel ways to deal with the basic difficulties inside the field of malignancy explore.

Cancer systems biology represents the application of systems biology approaches to deal with the investigation of how the intracellular networks of typical cells are disturbed during carcinogenesis to create viable predictive models that can help researchers and clinicians in the approvals of new treatments and medications. These annoyances are caused by the huge and progressing genomic and epigenetic instability in tumors adjusting the elements of wide range of molecules and systems in a cell and further entangled by the changes in the interactions with the local environment and also the individual as a whole through the tumorigenic process itself. Cancer systems biology approaches are therefore dependent on the utilization of computational and numerical techniques to decipher the multifaceted nature in cancer heterogeneity.

Track 7: Structural Genomics and Cancer

Structural genomics is a field of genomics that includes the portrayal of genome structures. This knowledge can be helpful in the act of controlling the genes and DNA portions of a species. Basic genomics depicts the 3-dimensional structure of every last protein that might be encoded by a genome – when particularly dissecting proteins; this is more commonly referred to as structural proteomics. The examination is expected to ponder the structure of the whole genome, by using both experimental and computational methods. While conventional structural prediction centers on the structure of a specific protein being referred to, structural genomics considers a bigger scale by expecting to decide the structure of each constituent protein encoded by a genome.

Track 8: Etiology-Specific Genomic Alterations

Numerous genetic and epigenetic events reveal tumor progression and define the characteristics of tumors. Advances in high-throughput technologies, similar to gene expression profiling, next generation sequencing, proteomics, and metabolomics, have empowered detailed molecular characterization of different tumors. The coordination and investigations of the high-throughput information have unwound numerous novel molecular variations and network alterations in tumors. These molecular changes incorporate different malignant growth driving transformations, gene fusions, amplification, deletion, and post-translational modifications, among others. A large number of these genomic events are being utilized in cancer diagnosis, though others are remedially focused with small-molecule inhibitors. Numerous genes/catalysts that play a role in DNA and histone modifications are additionally modified in different cancers, changing the epigenomic landscape amid malignant growth initiation and progression. Aside from protein-coding genes, studies are revealing the basic administrative roles played by noncoding RNAs and noncoding regions of the genome during malignancy progression. A considerable lot of these genomic and epigenetic events tandem to drive tumor improvement and metastasis. Simultaneous advances in genome-regulating innovations, similar to gene silencing and genome editing, are providing capacity to comprehend in detail the procedure of malignancy initiation, movement, and motioning and additionally opening up roads for therapeutic targeting.

Track 9: Cancer Biomarkers

Biomarkers are molecules that indicate traditional or abnormal method taking place in your body and should be an indication of associate underlying condition or sickness. Various kinds of molecules, like DNA (genes), proteins or hormones, will function as biomarkers, since all of them indicate one thing regarding your health. Biomarkers are also created by the cancer tissue itself or by different cells within the body in response to cancer. They can be found within the blood, stool, urine, tumour tissue, or different tissues or bodily fluids. Notably, biomarkers are not limited to cancer. There are biomarkers for heart condition, multiple sclerosis, and plenty of different diseases.   

Track 10: Genome-Based Cancer Typing

Individuals that inherit genomic mutation from their parents are at a greater risk of certain types of cancers. Familial cancer syndromes are the group of cancers where patients inherit genomes that do not function properly, increasing the risk of developing cancer.

Approximately one hundred familial cancer syndromes are known and this range is growing. The genes identified as increasing the risk of cancer are usually autosomal dominant (only one of the pair of chromosomes has to have the mutation in order for it to be expressed) though they'll even be chromosome recessive (both chromosomes should have the mutation for it to be expressed). The identification of those genes has improved designation and helped determine new cancer treatments.

The growing use of biological therapies that have an effect on cellular signaling pathways has revolutionized the treatment of cancer, a trend which will continue as treatment ways may be individualized to people once genomic typing of their cancer is known.

Track 11: Genotyping Technologies

Genotyping technologies give a robust toolset for examining the widest vary of genetic variation. Human genetic variation is gift in many alternative forms within the order, starting from giant, structural, and body changes to single ester polymorphisms (SNPs). There exists a broad vary of merchandise for analysis of genetic variation and genomic identification. Traditional strategies embody in place coupling, SNP genotyping, AFLP and microsatellite analysis; period PCR-based strategies mistreatment TaqMan Assays. Whereas additional advanced genomic identification techniques still develop, like array comparative genomic coupling. Genotyping may be a key tool within the analysis of factor variants related to sickness. Genotyping technologies have brought understanding to the means and consequences of the unbelievable quantity of variation in genomic polymer and its transcription merchandise.

Track 12: Cancer Diagnostics and Treatment

The earlier cancer is diagnosed and treated, the higher the possibility of its being cured. Some types of cancer such as those of the skin, breast, mouth, testicles, prostate, and rectum may be detected by routine self-exam or other screening measures before the symptoms become serious. Most cases of cancer area unit detected and diagnosed once a tumour is felt or once different symptoms develop. In a few cases, cancer is diagnosed incidentally as a result of evaluating or treating different medical conditions. Cancer diagnosing begins with a radical physical communication and a whole anamnesis. Laboratory studies of blood, urine, and stool will sight abnormalities which will indicate cancer. When a tumour is suspected, imaging tests like X-rays, computerized tomography (CT), resonance imaging (MRI), ultrasound, and fiber-optic examination examinations facilitate doctors verify the cancer's location and size. To confirm the diagnosing of most cancers, a diagnostic test must be performed within which a tissue sample is aloof from the suspected tumour and studied below a magnifier to check for cancer cells.

Track 13: Interrogating Cancer Genes with NGS-Based Approaches

Next-generation sequencing (NGS) technologies and knowledge have revolutionized cancer analysis and are increasingly being deployed to guide clinicians in treatment decision-making. NGS technologies have allowed taking an “omics” approach to cancer in order to reveal genomic, transcriptomic, and epigenomic landscapes of individual malignancies. Integrative multi-platform analyses are more and more utilized in large-scale projects that aim to completely characterize individual tumours still as general cancer sorts and subtypes. NGS technologies especially have contributed to “omics” approaches in cancer analysis, allowing large-scale integrative analyses that take into account many neoplasm samples. These types of studies have provided us with an unprecedented wealth of information, providing the background knowledge needed to make small-scale studies informative and relevant. Cancer analysis and care are presently poised to expertise vital progress catalyzed by accessible sequencing technologies which will profit each clinical and research-based effort.

Track 14: Genetic Risk Factors and Potential Therapeutic Targets

Cancer risk factors include exposure to chemicals or other substances, as well as certain behaviours. They additionally embrace things folks cannot management, like age and family history. A family history of certain cancers is often a symptom of a potential heritable cancer syndrome. Most cancer risk (and protective) factors are initially known in medicine studies. Cancer cells are rapidly evolving due to their unstable genome, which contributes to the development of new cancer clones with different gene expression profile (GEP). Manipulating the expression of the genes vital for the progression of the disease is important to beat its heterogeneousness. However, targeting overexpressed genes, retrieved from GEP analysis, would be economical for a particular quite a malignancy.

Track 15: Chemotherapy

Chemotherapy is a widely used treatment for cancer. The term chemotherapy refers to the medications that prevent cancer cells from dividing and growing. It does this by killing the dividing cells. A wide vary of medication is employed to realize these goals. The effectiveness depends to some extent on the stage of the cancer being treated. Adverse effects are often severe, and patients may have to discuss with their physician what to expect. The benefits of chemotherapy sometimes outweigh the danger of adverse effects.

Track 16: Cancer Immunotherapy

Cancer Immunotherapy is the artificial stimulation of the system to treat cancer, up on the system's aptitude to fight cancer. It is an application of the basic analysis of cancer immunology and a growing subspecialty of cancer studies. It exploits the actual fact that cancer cells typically have molecules on their surface that can be detected by the system, called tumor antigens; they are typically proteins or other macromolecules (e.g. carbohydrates). Immunotherapies are often categorised as active, passive or hybrid (active and passive). Active therapy directs the system to attack growth cells by targeting growth antigens. Passive immunotherapies enhance existing anti-tumor responses and embody the utilization of organism antibodies, lymphocytes and cytokines.

Track 17: Anti-Cancer Drugs

Anti-cancer drugs are referred to as anti-neoplastic agents or chemotherapy agents. They impact quickly dividing cancer cells and destroy them. They can be used alone as single-drug therapy or several at once as combination therapy. Various kinds of anti-cancer drugs are alkylating agents, antimetabolites, anti-microtubule agents, topoisomerase inhibitors, cytotoxic agents. They have severe adverse effects like hair loss, nausea and innate reflex, anemia etc.

Track 18: Overcoming Cancer Drug Resistance

Resistance to targeted treatment in cancer is really a moving target; there are opportunities to beat the resistance that develops. Though additional study is required, researchers believe understanding and predicting neoplasm resistance could translate into extra treatment choices within the clinical setting.

Treatment resistance that develops as cancer cells evolve is one of the most important limitations of targeted cancer therapies nowadays. During this progression, cancer cells not solely amendment their response to the drug being employed to treat the cancer, however additionally to several alternative medicine. In some cases, they become vulnerable to another drug, known as collateral sensitivity. In alternative cases, two medicines are at the same time resisted, cited as cross-resistance.

Track 19: Advances of Precision Medicine

Precision medicine is a term that describes personalized treatment that encompasses the employment of latest medicine and therapeutics, targeted to the requirements of a patient supported his/her own genetic, biomarker, phenotypic, or psychosocial characteristics. In particular, advances such as cell sorting, epigenetics, proteomics, metabolomics, and more are converging with informatics and other technologies in a manner that is rapidly expanding the scope of this field. Many current technologies are quickly enhancing the field of precision medicine. Recombinant biologic agents can now be used as replacement therapies, such as in the treatment of haemophilia, and electronic health records have created a rich and accessible database of clinical info which will be used for analysis and for clinical care guideline creation. Gene therapy, genetics, and next-generation deoxyribonucleic acid sequencing ways are maybe having the best effect; this can still advance with decreases in prices.

Track 20: Breast & Gynaecological Oncology

Breast cancer is a cancer that develops from breast tissue. Signs of breast cancer could embrace a lump within the breast, a modification in breast shape, dimpling of the skin, and fluid coming from the nipple, a new inverted nipple, or a red or scaly patch of skin. In those with distant unfold of the illness, there is also bone pain, swollen lymph nodes, shortness of breath, or yellow skin.

Gynecologic oncology may be a specialised field of medication that focuses on cancers of the feminine genital system, together with ovarian cancer, female internal reproductive organ cancer, duct cancer, cervical cancer, and female genital organ cancer. As specialists, they need in depth coaching within the diagnosing and treatment of those cancers.

Track 21: Radiation Oncology & Intervention Radiology

Radiation oncology may be a medical speciality that involves the controlled use of radiation to treat cancer either for cure, or to decrease pain and different symptoms caused by cancer. Radiation therapy may be a part of treatment in around four-hundredth of all patients cured of cancer. Radiation therapy are often applied safely to a large vary of cancers, and should be used alone or in conjunction with surgery, therapy and different treatments. It is sometimes fully non-invasive, and accessed through out-patient clinics. Radiation therapy may be extremely value effective cancer treatment.

Interventional Radiology (IR) refers to a range of techniques which rely on the use radiological image guidance (X-ray fluoroscopy, ultrasound, computed tomography [CT] or magnetic resonance imaging [MRI]) to precisely target therapy. Most IR treatments are minimally invasive alternatives to open and laparoscopic (keyhole) surgery. As several IR procedures begin with passing a needle through the skin to the target it's generally referred to as puncture surgery

Track 22: Pediatric Oncology

Pediatric oncology focuses on the analysis and treatment of cancers affecting youngsters and young adults. Common childhood cancers embody cancer; neuroblastoma, brain cancers, lymphomas, Wilms’ tumour, bone cancers, cell tumors, rhabdomyosarcoma, and retinoblastoma, the kinds of cancers that develop in children are usually totally different from cancers that develop in adults. Pediatric oncologists focus on treating infants, children, young adults and teenagers having cancer. Childhood cancers can develop because the results of DNA changes in cells that occur early in life, even before birth. Cancers that occur in youngsters are very rarely associated with any style of environmental or lifestyle issue. The pediatric oncology Branch is dedicated to enhancing results developed to extend the outcomes for the youngsters with tumour inclination syndromes, and in finding treatment of malady in youngsters

Track 23: Head and Neck Cancers

Cancers that are known jointly as head and neck cancers sometimes begin in the squamous cells that line the moist, tissue layer surfaces within the top and neck (for example, within the mouth, the nose, and therefore the throat). These epithelial cell cancers are usually remarked as epithelial cell carcinomas of the head and neck. Head and Neck Cancers also can begin within the secretion glands; however duct gland cancers are comparatively uncommon. Secretion glands contain many various sorts of cells which will become cancerous; therefore there are many various sorts of duct gland cancer.

Track 24: Organ Specific Cancers

Organ Specific Cancer is usually named based on the location of the Cancer cell in the body organ. There are more than 100 types of Cancer and it may occur anywhere in the human body. Breast Cancer is most common in Women, and Prostate cancer is common in Men. Lung cancer and colorectal cancer occurs commonly in both men and women. Cancer also defined by the type of the cell formed them, like epithelial or squamous cell. There are different types of Cancers based on location of cancer in the body organ. These types of Malignancies come under the category of Organ Specific Cancer.

Track 25: Endocrine and Neuroendocrine Tumours

An endocrine tumor is a mass that begins in the parts of the body that produce and release hormones. Because an endocrine tumor develops from cells that produce hormones, the tumor can also produce hormones. This can cause serious illness.

A neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a combination of hormone-producing endocrine cells and nerve cells. Neuroendocrine cells are found throughout the body in organs such as the lungs and gastrointestinal tract, including the stomach and intestines. Neuroendocrine cells perform specific functions, such as regulating air and blood flow through the lungs and controlling how quickly food moves through the gastrointestinal tract.

Track 26: Genomics Technologies, Concepts and Resources

Over the past 20-30 years, genomics technology evolutions have drastically transformed cancer researches. Powerful genomics platforms and tools have enabled whole-genome gene expression analysis, mutation analysis of millions of genetic markers in hundreds and thousands individuals, and ultimately the complete cancer genome sequencing in large clinical cohorts.

Track 27: Challenges & Ethics of Genomic Research

Genomic research carries great promise, however many ethical problems should be thought of whenever such testing is performed. There are moral concerns, as well as problems encompassing consent and also the uncertainty of the results of genomic testing; the challenge of incidental findings; and potential inequities in access to and benefit from such testing. Genomic testing is probably going to rework the follow of each benign and malignant haematology, however clinicians should rigorously think about these moral problems so as to form the foremost of this exciting and evolving technology.

Market Analysis

Scope and Importance:

The current utilization of genomic strategies has been extended to investigate the molecular premise of clinical phenotypes. This methodology could enable scientists to recognize hereditary changes that may recognize aggressive cancers from inactive ones, for instance. Similar methodologies could be utilized to study about the molecular basis of response to a given treatment, and also mechanism of resistance to treatment. The abundance of information rising up out of cancer genome considers progressively will be coordinated with patients' medical histories and clinical information. These coordinated outcomes could be utilized to grow more custom fitted ways to deal with cancer diagnosis and treatment, and in addition to enhance strategies for anticipating cancer hazard, prognosis, and reaction to treatment. Genomic tools will likewise be fundamental for breaking down outcomes from precision medicine clinical trials.

About Venue:

Abu Dhabi is the capital and the second most crowded city of the United Arab Emirates and furthermore capital of the Emirate of Abu Dhabi, the biggest of the UAE's seven emirates. Abu Dhabi lies on a T-formed island sticking into the Persian Gulf from the focal western drift. Abu Dhabi is the wealthiest emirate of the UAE as far as Gross Domestic Product (GDP) and per capital wage. Cancer is the third principal reason for death in Abu Dhabi. It is the third among nationals. It represents 16% of total deaths. There were around 427 demises caused by malignancy in 2015, 35% were nationals and 65% were emigrants. Tumor examine is basically proceeding in Asian countries near Abu Dhabi, so it is a sensible objective for Oncology gatherings.

Target Audience:

Oncologists

Cancer research institutes

Cancer Researchers

Genomic Researchers

Chemotherapists

Haematologists

Health Professionals

Medical Colleges

Pathologists

Pharmacologists

Radiologists

Biotechnologists

Business Entrepreneurs

Industry Professionals

Students and Delegates

Market Research:

Genomics in cancer market is required to achieve USD 9.22 billion by 2022. Expanding commonness of malignancy combined with appropriation of next generation sequencing for the diagnosis and treatment is required to fuel the market with future development opportunities. Expanding rates of cancer triggers the interest for financially effective and precise diagnostics in coming years. Genome sequencing ruled the general market in terms of income share at over 24.1% in 2014, inferable from related advantages, for example, exact conclusion and powerful outcomes. For instance, cancer whole genome sequencing helps in disclosure of novel disease related variations, for example, single nucleotide variants (SNVs), basic variations, and duplicate number changes. It additionally helps in contrasting ordinary and tumor DNA.

Furthermore, expanding interest for customized prescriptions in molecular characterization of malignant growth to recognize therapeutic targets is the factor ascribing towards the market development. Likewise, factors, for example, cost decrease in genome sequencing, developing social insurance consumption levels and improvement of compelling diagnostics and restorative methods for cancer are in charge of the potential development of genomics in cancer care.

List of Hospitals and Research Centers

Worldwide

Epworth Radiation Oncology

Georgetown Lombardi Comprehensive Cancer Center

James Cancer Hospital & Solove Research Institute

MacArthur Cancer Service

Oceania Oncology

Oslo Comprehensive Cancer Centre

Peter Maccallum Health Centre

Seattle Cancer Care Alliance

UNC Lineberger Comprehensive Cancer Center

Vall D’Hebron Institute of Oncology

Middle East

King Fahad National Center for Children’s Cancer Care and Research

Kuwait Cancer Center

Sheba Medical Center

Sheikh Khalifa Speciality Hospital

Special Neolif Medical Center

Abu Dhabi

Burjeel Hospital

NMC Healthcare

Madinat Mohamed bin Zayed HealthCare

Major Association and Societies

Worldwide

American Cancer Society

American Society of Clinical Oncology

International Agency for Research on Cancer

International Assocition for the Study of Lung Cancer

North American Association of Central Cancer Registries

Prevent Cancer Foundation

Susan G. Komen for the Cure

Union for International Cancer Control

World Cancer Research Fund International

MiddleEast

Israel Cancer Association

Reza Radiotherapy and Oncology Center

Turkish Association for Cancer Research and Control

Abu Dhabi

Breast Cancer Arabia

Positive Cancer Foundation

Cancer Patient Care Society - Rahma

Gulf International Cancer Center

List of Universities

Worldwide

Duke University

John Hopkins University

Stanford University

University of Helsinki

University of Maryland

University of Manchester

University of Nottingham

Washington University in St. Louis

MiddleEast

Bilkent University

Hebrew University of Jerusalem

Istanbul Sehir University

Tehran University of Medical Sciences

University of Wasit

Abu Dhabi

Mohammad Bin Rashid University of Medicine and Health Sciences

United Arab Emirates University

Zayed University

Projections: Growth by 5-10 yrs

Cancer death rates have declined 22 percent since the mid-1990s, on account of better medicines and prior discovery, as indicated by the American Cancer Society. With this new period still in its earliest stages, the cancer care network has high trusts in how the disclosures ahead may change the scene of treatment and survivorship. Somewhere in the range of 2006 and 2014, the U.S. government contributed $375 million to unravel tumor DNA—the formula of life. Analysts have concentrated on perusing the protein-coding qualities of twelve distinctive tumor types, including bosom, ovarian, kidney, colon, lung, head and neck and brain. Presently, the race is on to comprehend that data, and also other information pouring in, and make an interpretation of those revelations into new medications and counteractive action endeavors.

Related Conferences: Cancer Genomics Conferences | Oncology Congress | Genome Sequencing Events | Cancer Genomic Meeting 2019

Related Societies:

Middle East

Arab Medical Association against Cancer

Breast Cancer Foundation Dubai

Middle East Cancer Consortium

Middle-Eastern Association for Cancer Research

United States:

American Association for Cancer Research

American College of Nuclear Medicine

American Society of Clinical Oncology

Association of Community Cancer Center

Society for Immunotherapy of Cancer

Society for Neuro-Oncology

Europe:

European Society for Medical Oncology

French Society of Nuclear Medicine

Spanish Society of Nuclear Medicine

Asia-Pacific:

Asian Clinical Oncology Society

Hong Kong Anti-Cancer Society

Indian Cancer Society

Korean Cancer Association

Society of Indian Radiographers

Past Conference Report

World Cancer 2017

The 25th World Cancer Conference was organized on October 19-21, 2017 at Rome, Italy. World Cancer 2017 Congress has received a munificent response from all over the world. This has been conducted with the aim of promoting the developments of new perceptions and ideas for investigating the high level of knowledge reached by scientific community working in the field of Cancer & Oncology.

 The conference was organized around the theme ‘Together towards a cancer free tomorrow. The event imbedded a firm relation of future strategies in the field of Cancer Research with the scientific community.

This conference brought together Leading physicians, surgeons, Clinicians, Professors, Care Specialists, Students and other professionals in which many issues in Oncology field were discussed in depth to provide up-to-date information to the world. On the other hand, the meeting provided an opportunity for networking.

The eminent personalities at the conference were

·         Oliver Micke, Franziskus Hospital Bielefeld, Germany

·         Angiolo Gadducci, University of Pisa, Italy

·         Syed Azizur Rahman, University of Sharjah, UAE

·         Lloyd Jenkins, Budwig Center, Spain

Poster Evaluation Committee and the Winner:

World Cancer 2017 would like to acknowledge Dr. Javier Camacho for his evaluation of the poster session and we are glad to congratulate Ms. Sarah Konard, German Cancer Consortium (DKTK), Germany for receiving the Best Poster Award of the conference.

YRF Evaluation Committee and the Winner:

We would like to acknowledge Dr. Rong Shao for his evaluation of the poster session and we are glad to congratulate Perla Pérez Treviño, Tecnologico de Monterrey (ITESM), Mexico for receiving the Best Poster YRF Award of the conference.

Conference series LLC takes its pleasure to thank all the Organizing Committee Members, Chairs and Co-chairs, Speakers, Students, Media Partners and all who supported the conference in every aspect for the magnificent presence at the venue.


Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date January 30-31, 2019

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Supported By

Journal of Cancer Science & Therapy Journal of Carcinogenesis & Mutagenesis Journal of Cancer Clinical Trials

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by


Keytopics

  • Abdominal Imaging
  • Advances In Liquid Biopsy
  • Anal Cancer
  • Anti Cancer Drugs
  • Anti-cancer Drug Delivery
  • Biochemistry Of Cancer
  • Biological Therapy (Herceptin)
  • Bladder Cancer-cystectomy
  • Blastoma
  • Breast Cancer
  • Breast Magnetic Resonance Imaging
  • Breast Reconstruction Therapy
  • Breast Ultrasound
  • Breast-conserving Surgery Or Mastectomy
  • Breast-Sparing Surgery
  • Cancer Alternative Medicine
  • Cancer Bioinformatics
  • Cancer Biomarkers
  • Cancer Biopsy
  • Cancer Care Team
  • Cancer Cell Biology
  • Cancer Drugs And Cancer Vaccines
  • Cancer Inflamation And Immune Tolerance
  • Cancer Micro Environment
  • Cancer Nanotechnology
  • Cancer Nursing And Care
  • Cancer Pharma Industry
  • Cancer Pharmacology
  • Cancer Prognosis And Predictive Elements
  • Cancer Proteomics
  • Cancer Staging
  • Cancer Statistics
  • Cancer Stem Cells
  • Cancer Trends And Opportunities
  • Cardiac Imaging
  • Cell Free Biomarkers
  • Chemotherapy
  • Clinical Application For Biomarkers
  • Clinical Breast Exam And Breast Self-exam
  • Clinical Trials And Case Report
  • Clinicopathology
  • Colorectal Adenoma And Cancer
  • Colorectal Cancer
  • Computational Oncology
  • Computer Assisted Tomography
  • Curative Cancer Treatment
  • Ductal Carcinoma In Situ (DCIS)
  • Early & Advanced Breast Cancer Systemic Therapy
  • Economic Impact On Cancer
  • Endocrine And Neuroendocrine Tumors
  • Endocrine Malignancies
  • Entrepreneurs Investment Meet
  • ER Status
  • Etiology Of Cancer
  • Ewing Sarcoma
  • Factors Associated With Cancer Prevalence
  • Gastrointestinal Cancer Immunotherapy
  • Gastrointestinal Cancers
  • Gene Markers
  • Genotypic Mapping- Basic Understanding
  • Global Market For Cancer Treatments
  • Gynaecologic Oncology
  • Head And Neck Cancers
  • Hematologic Cancers
  • Hepatocellular Carcinoma
  • HER2 Status.
  • Hereditary Cancers
  • Hormone Replacement Therapy (HRT).
  • Immuno Oncology
  • Inflammatory Breast Cancer
  • Interventional Radiology
  • Invasive Cancer
  • Juvenile Myelomonocytic Leukemia (JMML)
  • Luminal A And B Breast Cancer
  • Lumpectomy
  • Lymph Node Status
  • Lymph Node Surgery
  • Male Breast Cancer
  • Mammography
  • Metastasis
  • Metastatic Breast Cancer
  • Molecular Breast Imaging
  • Molecular Epidemiology Of Cancer
  • Nanoparticles In Cancer Therapy
  • Neuro Oncology
  • Neuro-oncology
  • Neuroradiology
  • Non-Hodgkin Lymphoma
  • Novel Approaches To Cancer Therapeutics
  • Nuclear Medicine
  • Oncology And Radiology
  • Oncology Case Reports
  • Organ Based Cancers
  • Ovarian Cancer
  • Oxidative Stress Biomarkers
  • Pain Management
  • Palliative Cancer Treatment
  • Pancreatic Cancer
  • Parathyroid Cancer
  • Pathophysiology Of Cancer
  • Pediatric Oncology
  • PEM And EIT
  • Personalized Cancer Screening
  • Personalized Treatment Approach
  • Precision Medicine
  • Predictive Cancer Biomarkers
  • Prognostic Biomarkers
  • Prostaglandins
  • Prostate Cancer
  • Proteomics In Cancer
  • Psychosocial Support And Vocational Counseling
  • Radiation Oncology
  • Radiation Therapy
  • Remission
  • Renal Cell Carcinoma
  • Reproductive Cancer
  • Segmental Mastectomy
  • Serum Tumour
  • Signs, Symptoms & Stages Of Breast Cancer
  • Squamocellular Carcinoma Blood Disorders
  • Surgical Oncology
  • Tissue Flap Surgery
  • Treatment Of Breast Cancer During Pregnancy
  • Tumor Virology
  • Types Of Biomarker And Biomarkers
  • Types Of Cancer
  • Types Of Cancers
  • Urinary Biomarkers
  • Urothelial Carcinoma-associated-1
  • Veterinary Hematology